Literature DB >> 1977419

Alzheimer disease and the dementia of Parkinson disease: comparative investigations.

M E Mahler1, J L Cummings.   

Abstract

Intellectual abnormalities are common in Parkinson disease (PD), occurring in a majority of patients and exhibiting a spectrum of severity from mild to severe. Alzheimer disease (AD) has been posited as the cause of dementia in PD. Comparative neuropsychological studies, however, show differences in memory, language, and frontal lobe functions between AD and PD patients even when the two groups have comparably severe dementia syndromes. The AD-type neuropathology occurs in 10-60% of PD patients, and dementia is usually overt when AD pathology is identified at autopsy. The AD changes are less frequent than intellectual deterioration in PD, and dementia has been observed in PD patients without AD pathology. Therefore, concurrent AD cannot be the cause of all cases of dementia in PD. Cholinergic deficits occur in some PD patients, but cholinergic deficits have been described in patients without dementia and dementia has been documented in patients without cholinergic system abnormalities. Dopaminergic disturbances contribute to the dementia of PD. Differences in neuropeptide concentrations, electrophysiologic responses, and cerebral metabolism also support pathophysiologic distinctions between AD and the dementia of PD. Genetic investigations suggest a role for heredity in AD, whereas PD appears to be an acquired, nongenetic disorder. These studies indicate that despite areas of overlap in clinical symptoms and neuropathology, AD and the dementia of PD are largely distinct.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1977419     DOI: 10.1097/00002093-199040300-00002

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  10 in total

1.  Magnetization transfer measurements of the hippocampus in patients with Alzheimer's disease, vascular dementia, and other types of dementia.

Authors:  H Hanyu; T Asano; T Iwamoto; M Takasaki; H Shindo; K Abe
Journal:  AJNR Am J Neuroradiol       Date:  2000-08       Impact factor: 3.825

2.  An update on brain imaging in parkinsonian dementia.

Authors:  Myria Petrou; Vikas Kotagal; Nicolaas I Bohnen
Journal:  Imaging Med       Date:  2012-04

Review 3.  Neuroimaging and cognition in Parkinson's disease dementia.

Authors:  Lisa C Silbert; Jeffrey Kaye
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

4.  Gait speed in Parkinson disease correlates with cholinergic degeneration.

Authors:  Nicolaas I Bohnen; Kirk A Frey; Stephanie Studenski; Vikas Kotagal; Robert A Koeppe; Peter J H Scott; Roger L Albin; Martijn L T M Müller
Journal:  Neurology       Date:  2013-09-27       Impact factor: 9.910

Review 5.  Magnetic resonance imaging and magnetic resonance spectroscopy in dementias.

Authors:  Y Y Hsu; A T Du; N Schuff; M W Weiner
Journal:  J Geriatr Psychiatry Neurol       Date:  2001       Impact factor: 2.680

Review 6.  Imaging of cholinergic and monoaminergic neurochemical changes in neurodegenerative disorders.

Authors:  Nicolaas I Bohnen; Kirk A Frey
Journal:  Mol Imaging Biol       Date:  2007 Jul-Aug       Impact factor: 3.488

7.  Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease--effect of L-Dopa.

Authors:  M Strittmatter; G F Hamann; D Strubel; H Cramer; K Schimrigk
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 8.  The cholinergic system and Parkinson disease.

Authors:  Nicolaas I Bohnen; Roger L Albin
Journal:  Behav Brain Res       Date:  2010-01-07       Impact factor: 3.332

Review 9.  GRK5 Deficiency Causes Mild Cognitive Impairment due to Alzheimer's Disease.

Authors:  William Z Suo
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

10.  Rivastigmine for the treatment of dementia associated with Parkinson's disease.

Authors:  Jennifer L Reingold; John C Morgan; Kapil D Sethi
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.